Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

New blinded preliminary BRTX-100 data described this past Saturday at prestigious "2025 Winners in Industry Innovations in MSK Health” presentation - - Among other positive preliminary data analyses, ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This ...

AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

The University of Chicago will receive up to $130 million in funding over the next 10 years as part of a new drug research ...

SAN DIEGO - Dare Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has been awarded a Notice of Award of a grant from the National Institute of Allergy and ...

Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...